<DOC>
	<DOCNO>NCT01957410</DOCNO>
	<brief_summary>To evaluate somatosensory evoke potential ( SEPs ) motor evoke potential ( MEPs ) obtain electroencephalography ( EEG ) electromyography ( EMG ) use detect change cortical plasticity responder single IV infusion ketamine compare non-responders .</brief_summary>
	<brief_title>A Study Investigate Evoked Potentials Markers Ketamine-induced Cortical Plasticity Patients With Major Depressive Disorder</brief_title>
	<detailed_description>This study conduct patient Major Depressive Disorder ( MDD ) divide 2 sequential cohort . Cohort 1 conduct 12 patient single center . For patient , 4 sequential phase : screen phase 6 week , open-label treatment phase 4 week , optional open-label treatment phase 1 week , follow-up phase 1 week ( applicable ) . Cohort 2 conduct 20 patient multicenter , double-blind ( neither physician patient know treatment patient receives ) , randomize ( study drug assign chance ) , placebo-controlled ( inactive substance compare drug test whether drug real effect clinical trial ) design . For patient , 4 sequential phase : screen phase 6 week , double-blind treatment phase 4 week , optional open-label treatment phase 1 week , follow-up phase 1 week ( applicable ) . The total study duration patient maximally 12 week . Participant safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Patient must medically stable Patient must meet Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) diagnostic criterion Major Depressive Disorder ( MDD ) , without psychotic feature , base upon clinical assessment confirm Mini International Psychiatric Interview ( MINI ) Patient must inadequate response least 2 antidepressant , one current episode depression Patient must Inventory Depressive Symptomatology 30item Clinicianrated ( IDSC30 ) total score â‰¥ 34 Screening Day 1 Women must postmenopausal , surgically sterile , , heterosexually active , practice highly effective method birth control Men heterosexually active woman childbearing potential must agree use double barrier method birth control donate sperm study 3 month receive last dose study drug Patient current sign and/or symptom liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , metabolic disturbance Patient primary DSMIV diagnosis current ( active ) generalize anxiety disorder ( GAD ) , panic disorder , obsessive compulsive disorder ( OCD ) , posttraumatic stress disorder ( PTSD ) , anorexia nervosa , bulimia nervosa Patient current diagnosis bipolar disorder , mental retardation , cluster b personality disorder ( e.g. , borderline personality disorder , antisocial personality disorder , etc ) Patient current prior diagnosis psychotic disorder MDD psychosis Patient respond treatment electroconvulsive therapy ( ECT ) current episode depression Patient suicidal ideation intent act , homicidal ideation/intent , Screening phase per Investigator 's clinical judgment Patient significant primary sleep disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Ketamine</keyword>
	<keyword>Evoked potential</keyword>
	<keyword>Somatosensory evoke potential</keyword>
	<keyword>Motor evoke potential</keyword>
	<keyword>Cortical plasticity</keyword>
</DOC>